Absence of p53 Mutations in Malignant Mesotheliomas

American Journal of Respiratory Cell and Molecular Biology

Volumn 16, Issue 1, 1997, Pages 9-13

  Mor, Orna ^a   Yaron, Pnina ^b   Huszar, Monica ^b   Yellin, Allon ^b   Jakobovitz, Orit ^b   Brok Simoni, Frida ^b   Rechavi, Gideon ^b   Reichert, Nira ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PRIMER DNA;

ADULT; AGED; ARTICLE; CELL CULTURE; EXON; FEMALE; GENETICS; HUMAN; MALE; MESOTHELIOMA; MIDDLE AGED; MUTATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; AGED; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EXONS; FEMALE; GENES, P53; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUMOR CELLS, CULTURED;

EID: 0030636533     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/ajrcmb.16.1.8998073     Document Type: Article

References (44)

1. Rom, W. N., W. D. Travis, and A. R. Brody. 1991. Cellular and molecular basis of the asbestos-related diseases. Am. Rev. Respir. Dis. 143:408-422.
2. Libbus, B. L., and J. E. Craighead. 1988. Chromosomal translocation with specific break points in asbestos-induced rat mesotheliomas. Cancer Res. 48:6455-6461.
3. Hansteen, I. L., B. Hilt, J. T. Lien, V. Skaug, and A. Haugen. 1988. Karyotypic changes in preclinical and subsequent stages of malignant mesotheliomas: a case report. Cancer Genet. Cytogenet. 70:94-98.
4. Bello, M. J., J. A. Rey, M. J. Aviles, M. Arevalo, and J. Benitez. 1987. Cytogenetic findings in an effusion secondary from pleural mesothelioma. Cancer Genet. Cytogenet. 29:75-79.
5. Gibas, Z., P. Frederick, K. H. Antman, S. Bernal, R. Stahel, and A. A. Sandberg. 1986. Chromosome changes in malignant mesothelioma. Cancer Genet. Cytogenet. 20:191-201.
6. Popescu, N. C., A. P. Chahinian, and J. A. DiPaolo. 1988. Nonrandom chromosome alterations in human malignant mesothelioma. Cancer Res. 48:142-147.
7. Vogelstien, B. 1990. A deadly inheritance. Nature 348:681-682.
8. Lane, D. P. 1992. p53, guardian of the genome. Nature 358:15-16.
9. Perry, M. E., and A. J. Levine. 1993. Tumour suppressor p53 and the cell cycle. Curr. Opin. Genet. Dev. 3:50-54.
10. Canman, C. E., and M. B. Kastan. 1995. Induction of apoptosis by tumor suppressor genes and oncogenes. Semin. Cancer Biol. 6:17-25.
11. Levine, A. J. 1992. The p53 tumor suppressor gene. N. Engl. J. Med. 326:1350-1352.
12. Cote, R. J., S. C. Jhanwar, S. Novick, and A. Pellicer. 1992. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res. 51:5410-5416.
13. Metcalf, R. A., J. A. Welsh, W. P. Bennet, M. B. Seddon, T. A. Lehman, K. Pelin, K. Linnainmaa, L. Tammilehto, K. Mattson, B. I. Gerwin, and C. C. Harris. 1992. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res. 52:2610-2615.
14. Bonetta, L. 1994. Tumour-suppressor genes. Open questions on p16. Nature 370:180.
15. Ramael, M., G Lemmens, C. Eerdekens, C. Buysse, I. Deblier, W. Jacobs, and E. Van Mark. 1992. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium, J. Pathol. 168: 371-375.
16. Kafiri, G., D. M. Thomas, A. Shepherd, T. Krausz, D. P. Lane, and P. A. Hall. 1992. p53 expression is common in malignant mesothelioma. Histopathology 21:331-334.
17. Mor, O., I. Hakim, H. Stiebel, N. Amariglio, Z. Grossman, F. BrokSimoni, D. Nass, A. Cohen, M. Mandel, and G. Rechavi. 1994. Application of DGGE and SSCP to the analysis of point mutations in the p53 tumour suppressor gene. Mol. Biol. (Life Sci. Adv.) 13:53-61.
18. McPherson, M. J., P. Quirke, and G. R. Taylor.1991. PCR a practical approach. In The Practical Approach Series. D. Rickwood and B. D. Hames, editors. Oxford University Press, New York.
19. Murakami, Y., K. Hayashi, and T. Sekiya. 1991. Detection of aberrations of the p53 alleles and the gene transcript in human tumour cell lines by single-strand polymorphism analysis. Cancer Res. 51:3356-3361.
20. Sugimoto, K., H. Toyoshima, R. Sakai, K. Miagawa, K. Hagiwara, H. Hirai, F. Ishikawa, and F. Takaku. 1991. Mutations of the p53 Gene in Lymphoid Leukemia. Blood 77:1153-1156.
21. Felix, C. A., C. C. Kappel, T. Mitsudomi, M. M. Nau, M. Tsokos, G. D. Crouch, P. D. Nisen, N. J. Winick, and L. J. Helman. 1992. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res. 52:2243-2247.
22. Yamada, Y., T. Yoshida, K. Hayashi, T. Sekiya, J. Yokota, S. Hirohashi, K, Nakatani, H. Naakano, T. Sugimura, and M. Terada. 1991. p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. Cancer Res. 51:5800-5805.
23. Orita, M., Y. Suzuki, T. Sekiya, and K. Hayashi. 1989. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5:874-879.
24. Lerman, L. S. and K. Silverstein. 1987. Computational stimulation of DNA melting and its application to denaturing gradient gel electrophoresis. Methods Enzymol. 155:482-500.
25. Abrams, E. S., S. E. Murdaugh, and L. S. Lerman. 1990. Comprehensive detection of single base changes in human genomic DNA using denaturing gradient gel electrophoresis and a GC clamp. Genomics 7:463-475.
26. Mor, O., Z. Grossman, O. Jakobovitz, F. Brok-Simoni, and G. Rechavi. 1992. Artifactual p53 point mutations: possible effect of gene secondary structure on PCR and direct sequence analysis. Lancet 340:1236.
27. Lee-Jackson, D., J. L. Abbruzzese, and M. Bar-Eli. 1993. Artifactual frame shift p53 mutation at codon 249 detected with the cyclist DNA sequencing method. Biotechnology 15:363-364.
28. Marx, J. 1993. How p53 suppresses cell growth. Science 262:1644-1645.
29. Schwartz, D., N. Goldfinger, and V. Rotter. 1993. Expression of p53 protein in spermatogenesis is confined to the tetraploid pachytene primary spermatocytes. Oncogene 8:1487-1494.
30. Harris, C. C., and M. Hollstein. 1993. Clinical implications of the p53 tumor suppressor gene. N. Engl. J. Med. 329:1318-1327.
31. Harris, C. C. 1993. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262:1980-1981.
32. Beck, J. S., A. E. Kwitek, P. H. Cogan, A. K. Metzger, G. M Duyk, and V. C. Sheffield. 1993. A denaturing gradient gel electrophoresis assay for sensitive detection of p53 point mutations. Hum. Genet. 91:25-30.
33. Sheffield, V. C., J. S. Beck, A. E. Kwitek, D. W. Sandstorm, and E. M. Stone. 1993. The sensitivity of single strand conformation polymorphism analysis for the detection of single base substitutions. Genomics 16: 325-332.
34. Segers, K., H. Backhovens, S. K. Singh, J. Devoecht, M. Ramael, C. Vanbroeckhoven, and E. Vanmarck. 1995. Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human-malignant mesothelioma. Virchows Arch. 427:431-436.
35. Suzuki, Y., A. Weston, and R. Ashley. 1995. Immunocytochemical analysis of oncoproteins and growth-factors in human-malignant mesothelioma. Oncol. Rep. 2:897-902
36. Wu, X., H. Bayle, D. Olson, and A. J. Levine. 1993. The p53-MDM2 autoregulatory feedback loop. Genes Dev. 7:1126-1132.
37. Vousden, K. H. 1995. Regulation of the cell cycle by viral oncoproteins Semin. Cancer Biol. 6:109-116.
38. Gerwin, B. I. 1994. Asbestos and the mesothelial cell: a molecular trail to mitogenic stimuli and suppressor gene suspects. Am. J. Respir. Cell Mol. Biol. 11:507-508.
39. Flejter, W. L., F. P. Li, K. H. Antman, and J. R. Testa. 1989. Recurring loss involving chromosomes 1, 3 and 22 in malignant mesothelioma: possible site of tumour suppressor genes. Genes Chrom. Cancer 1:148-154.
40. Taguchi, T., S.C. Jhanwar, J. M. Siegfried, S. M. Keller, and J. R. Testa. 1993. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human-malignant mesothelioma. Cancer Res. 53:4349-4355.
41. Cheng, J. Q., S. C. Jhanwar, W. M. Klein, D. W. Bell, W. C. Lee, D. A. Altomare, T. Nobori, O. I. Olopade, A. J. Buckler, and J. R. Testa. 1994. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 54:5547-5551.
42. Kratzke, R. A., G. A. Otterson, C. E. Lincoln, S. Ewing, H. Oie, J. Geradts, and F. J. Kaye. 1995. Immunohistochemical analysis of the p16(ink4) cyclin-dependent kinase inhibitor in malignant mesothelioma. J. Natl. Cancer Inst. 87:1870-1875.
43. Kastan, M. B., Q. Zhan, W. S. El-Deiry, F. Carrier, J. Tyler, W. V. Walsh, B. Plunkett, B. Vogelstein, and A. J. Fornace. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-595.
44. El-Deiry, W. S., T. Tokino, V. E. Veiculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, apotential mediator of p53 tumor suppression. Cell 75:817-825.